Glycopyrrolate: uses, dosing, side effects & brands

Glycopyrrolate is an anticholinergic sold in the U.S. under 8 brand and generic names, for hyperhidrosis, drug-induced abnormalities and peptic ulcer. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Drug class: Anticholinergic
Treats (across its forms): Hyperhidrosis, Drug-Induced Abnormalities and Peptic Ulcer
Available as: Powder · Liquid · Tablet, orally disintegrating · Injectable · Solution · Tablet
Sold as: 8 products — Seebri Neohaler, Cuvposa and Dartisla ODT, and others
Prescription?: Prescription only
Generic available?: Yes
What the pharmacy pays: about $0.21 per ml — not your price

How Cuvposa is dosed

From the FDA label for Cuvposa (application NDA022571). Other glycopyrrolate products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

CUVPOSA must be measured and administered with an accurate measuring device [see Patient Counseling Information (17) ]. Initiate dosing at 0.02 mg/kg orally three times daily and titrate in increments of 0.02 mg/kg every 5-7 days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily not to exceed 1.5-3 mg per dose based upon weight. For greater detail, see Table 1 . During the four-week titration period, dosing can be increased with the recommended dose titration schedule while ensuring that the anticholinergic adverse events are tolerable. Prior to each increase in dose, review the tolerability of the current dose level with the patient's caregiver. CUVPOSA should be dosed at least one hour before or two hours after meals. The presence of high fat food reduces the oral bioavailability of CUVPOSA if taken shortly after a meal [see Clinical Pharmacology (12.3) ]. Table 1: Recommended Dose Titration Schedule (each dose to be given three times daily) Weight Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Dose Level 5 kg lbs (~0.02 mg/kg) (~0.04 mg/kg) (~0.06 mg/kg) (~0.08 mg/kg) (~0.1 mg/kg) 13-17 27-38 0.3 mg 1.5 mL 0.6 mg 3 mL 0.9 mg 4.5 mL 1.2 mg 6 mL 1.5 mg 7.5 mL 18-22 39-49 0.4 mg 2 mL 0.8 mL 4 mL 1.2 mg 6 mL 1.6 mg 8 mL 2.0 mg 10 mL 23-27 50-60 0.5 mg 2.5 mL 1.0 mg 5 mL 1.5 mg 7.5 mL 2.0 mg 10 mL 2.5 mg 12.5…

Everything below is the FDA label for Cuvposa (liquid). Glycopyrrolate is also sold as powder, tablet, orally disintegrating, injectable, solution and tablet, and those are different medicines to take — follow the label for the one you were prescribed.

Cuvposa side effects

The following serious adverse reactions are described elsewhere in the labeling: Constipation or intestinal pseudo-obstruction [see Warnings and Precautions (5.1) ] Incomplete mechanical intestinal obstruction [see Warnings and Precautions (5.2) ] The most common adverse reactions reported with CUVPOSA are dry mouth, vomiting, constipation, flushing, and nasal congestion. The most common adverse reactions (incidence ≥30%) are dry mouth, vomiting, constipation, flushing, and nasal congestion. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Merz Pharmaceuticals, LLC at 1-844-469-6379 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to CUVPOSA in 151 subjects, including 20 subjects who participated in an 8-week placebo-controlled study (Study 1) and 137 subjects who participated in a 24-week open-label study (six subjects who received CUVPOSA in the placebo-controlled study and 131 new subjects). Table 2 presents adverse reactions reported by ≥ 15% of CUVPOSA-treated subjects from the placebo-controlled clinical trial. Table 2: Adverse…

Who shouldn’t take Cuvposa

CUVPOSA is contraindicated in: Patients with medical conditions that preclude anticholinergic therapy (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis). Patients taking solid oral dosage forms of potassium chloride. The passage of potassium chloride tablets through the gastrointestinal (GI) tract may be arrested or delayed with coadministration of CUVPOSA. Medical conditions that preclude anticholinergic therapy. ( 4 ) Concomitant use of solid oral dosage forms of potassium chloride. ( 4 )

Cuvposa drug interactions

Digoxin tablets: Use with glycopyrrolate can increase digoxin serum levels. Monitor patients and consider use of alternative dosage forms of digoxin. ( 7 ) Amantadine: Effects of glycopyrrolate may be increased with concomitant administration of amantadine. Consider decreasing the dose of glycopyrrolate during concomitant use. ( 7 ) Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin. Consider dose reduction when used with glycopyrrolate. ( 7 ) Haloperidol or levodopa: Glycopyrrolate may decrease serum levels of haloperidol or levodopa. Consider a dose increase when used with glycopyrrolate. ( 7 ) Drugs Affected by Reduced GI Transit Time Glycopyrrolate reduces GI transit time, which may result in altered release of certain drugs when formulated in delayed- or controlled-release dosage forms. The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4) ]. Digoxin administered as slow dissolution oral tablets may have increased serum levels and enhanced action when administered with glycopyrrolate. Monitor patients receiving slow dissolution digoxin for increased action if glycopyrrolate is coadministered regularly. Consider the use of other oral dosage forms of digoxin (e.g., elixir or capsules). Amantadine The anticholinergic effects of glycopyrrolate may be increased with concomitant administration of amantadine. Consider decreasing the dose of glycopyrrolate during coadministration of amantadine. Drugs Whose Plasma Levels May be Increased by Glycopyrrolate Coadministration of glycopyrrolate may result in increased levels of certain drugs. Atenolol's bioavailability may be increased with coadministration of glycopyrrolate. A reduction in the atenolol dose may be needed. Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin's pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. Drugs Whose Plasma Levels May be Decreased by Glycopyrrolate Coadministration of glycopyrrolate may result in decreased levels of certain drugs. Haloperidol's serum level may be decreased when coadministered with glycopyrrolate, resulting in worsening of schizophrenic symptoms, and development of tardive dyskinesia. Closely monitor patients if coadministration cannot be avoided. Levodopa's therapeutic effect may be reduced with glycopyrrolate administration. Consider increasing the dose of levodopa.

Every glycopyrrolate product we track (8)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Glycopyrrolate products
#	Drug	Rating	Type	Form	Generic?	Pharmacy pays
1	Seebri Neohaler	70/100	Prescription	Powder	Generic	$0	View →
2	Cuvposa	Not yet rated	Prescription	Liquid	Generic	$0	View →
3	Dartisla ODT	Not yet rated	Prescription	Tablet	Generic	$0	View →
4	Glycopyrrolate	Not yet rated	Prescription	Injectable	Generic	$0	View →
5	Glyrx-Pf	Not yet rated	Prescription	Injectable	Generic	$0	View →
6	Lonhala Magnair Kit	Not yet rated	Prescription	Solution	Generic	$0	View →
7	Robinul	Not yet rated	Prescription	Tablet	Generic	$0	View →
8	Robinul Forte	Not yet rated	Prescription	Tablet	Generic	$0	View →

What glycopyrrolate pills look like

Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.

Glycopyrrolate pill imprints
Imprint	Strength	Colour	Shape	Maker
Y;51	2 mg	white	round	—

Combination products containing glycopyrrolate

A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.

Glycopyrrolate recalls

From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.

How long glycopyrrolate keeps

No glycopyrrolate label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.

Does glycopyrrolate expire? The in-use limits and storage rules from its labels

Glycopyrrolate and breastfeeding

From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.

No information is available on the use of glycopyrrolate during breastfeeding. Because glycopyrrolate is a quaternary ammonium compound, it is not likely to be absorbed and reach the bloodstream of the infant, especially when given by inhalation or topically on the skin. Long-term oral use of glycopyrrolate might reduce milk production or milk letdown, but a single dose is unlikely to interfere with breastfeeding. During long-term use, observe for signs of decreased lactation such as poor weight gain. The inhaled form of glycopyrrolate has not been studied, but is unlikely to cause effects in the breastfed infant or on milk production.

Full LactMed record for glycopyrrolate: levels in milk, effects in breastfed infants, and the drugs it would consider instead

National Institute of Child Health and Human Development, record revised January 15, 2026. LactMed states its information is not a substitute for professional judgement.

What people report to the FDA about glycopyrrolate

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 9,273 reports naming glycopyrrolate, and the FDA flagged 89% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

dyspnoea1,543 reports
asthma977 reports
cough920 reports
pneumonia813 reports
wheezing799 reports
malaise564 reports
chronic obstructive pulmonary disease547 reports
fatigue537 reports

Read these as a signal, not a rate. A report does not mean glycopyrrolate caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.

Source: openFDA drug/event (FAERS), retrieved July 25, 2026.

Related calculators

How long it stays in your system →

Frequently asked questions

What is Cuvposa?

CUVPOSA is an anticholinergic drug available as an oral solution containing 1 mg glycopyrrolate per 5 mL.

What kind of drug is glycopyrrolate?

The FDA classifies glycopyrrolate as an anticholinergic. Anticholinergic drugs block acetylcholine, the chemical messenger of the body's "rest and digest" nervous system, by occupying its muscarinic receptors. This eases muscle spasms, dries up secretions, relaxes the bladder and airways, and speeds the heart, depending on the tissue. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

Can you take glycopyrrolate with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run glycopyrrolate against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is glycopyrrolate sold under?

We track 8 glycopyrrolate-containing products in the U.S.: Seebri Neohaler, Cuvposa, Dartisla ODT, Glycopyrrolate, Glyrx-Pf, Lonhala Magnair Kit, Robinul and Robinul Forte. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does glycopyrrolate come in?

Across the brands we track, glycopyrrolate is currently marketed as powder, liquid, tablet, orally disintegrating, injectable, solution and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic glycopyrrolate?

Yes. Our catalog lists 1 generic glycopyrrolate product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

Has glycopyrrolate been recalled?

The FDA's Enforcement database lists 4 recall records whose product description mentions glycopyrrolate. The most recent: Glycopyrrolate Injection (Jul 16, 2026). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Cite this page

APA: pharmaranks. (2026, July 24). Glycopyrrolate: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/glycopyrrolate
MLA: “Glycopyrrolate: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/glycopyrrolate.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for glycopyrrolate on DailyMed (NIH) ↗.